Suiseng inj. susp. i.m. vial

Country: Belgium

Language: English

Source: AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

Active ingredient:

Clostridium novyi toxoid ; Clostridium perfringens type C toxoid ; Escherichia coli F4ab fimbrial adhesin ; Eschericia coli LT-enterotoxoïd ; Escherichia coli F4ac fimbrial adhesin ; Escherichia coli F5 fimbrial adhesin ; Escherichia coli F6 fimbrial adhesin

Available from:

Laboratorios Hipra S.A.

ATC code:

QI02AT01

INN (International Name):

Clostridium Perfringens; Escherichia Coli Enterotoxin LT; Clostridium Novyi Toxoid; Escherichia Coli Adhesins

Pharmaceutical form:

Suspension for injection

Composition:

Clostridium Perfringens; Escherichia Coli Enterotoxin LT; Clostridium Novyi Toxoid; Escherichia Coli Adhesins

Administration route:

Intramuscular use

Therapeutic group:

pig

Therapeutic area:

Escherichia

Product summary:

CTI code: 347286-03 - Pack size: 50 doses - Commercialisation status: NO - Delivery mode: Medical prescription; CTI code: 347286-01 - Pack size: 10 doses - Commercialisation status: NO - CNK code: 2671618 - Delivery mode: Medical prescription; CTI code: 347295-01 - Pack size: 10 doses - Commercialisation status: NO - Delivery mode: Medical prescription; CTI code: 347286-02 - Pack size: 25 doses - Commercialisation status: NO - Delivery mode: Medical prescription; CTI code: 347295-02 - Pack size: 25 doses - Commercialisation status: NO - Delivery mode: Medical prescription; CTI code: 347295-03 - Pack size: 50 doses - Commercialisation status: YES - CNK code: 2671634 - Delivery mode: Medical prescription; CTI code: 347295-04 - Pack size: 125 doses - Commercialisation status: NO - Delivery mode: Medical prescription

Authorization status:

Commercialised: No

Authorization date:

2009-09-15